TRU-016: Phase Ib started

Emergent began an open-label, U.S. Phase Ib trial to evaluate IV TRU-016 given weekly for 8 weeks followed by 4 monthly doses plus

Read the full 233 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE